The U.S. Food and Drug Administration approved Eli Lilly’s oral selective estrogen receptor degrader (SERD), Inluriyo (formerly imlunestrant), for adults with metastatic, estrogen receptor-positive, HER2-negative breast cancer harboring ESR1 mutations. Inluriyo demonstrated a 38% reduction in the risk of disease progression or death in the EMBER-3 trial, extending progression-free survival by 5.5 months compared to hormone-suppressing therapies. The therapy offers an all-oral alternative targeting a common mechanism of hormonal therapy resistance. Lilly’s oncology head highlighted its role advancing oral breast cancer treatments.